Diginex is betting big on the booming market for supply-chain compliance software, but the market is punishing the stock even as the company unveils a new end-to-end platform. Shares have lost more than 40% over the past month, and the selling pressure shows no sign of letting up.
The company on June 4 launched an integrated version of its Risk-to-Remedy solution, combining three components into a single offering: LUMEN for supply-chain risk analysis, APPRISE for direct worker engagement, and expertise from The Remedy Project, which Diginex acquired to handle grievance mechanisms and remediation processes. The platform is designed to deliver worker-level evidence, prioritized corrective actions, and reports that can withstand regulatory scrutiny.
That regulatory push is the reason for the product timing. The platform aims to address multiple overlapping regimes — Germany’s supply-chain due diligence law, the EU’s Corporate Sustainability Due Diligence Directive (CSDDD), the EU Forced Labour Regulation, and similar legislation in the UK, Australia, and Canada. Diginex pegs the total addressable market for human rights and supply-chain due diligence at $3.8 billion in 2025, expanding to $9.6 billion by 2034.
Navigating overlapping compliance regimes — from CSDDD to UK supply-chain laws — demands meticulous documentation. But risk assessment isn’t limited to supply chains; your own workplace poses hazards that require equally rigorous records. A free toolkit with 41 ready-to-use templates helps you document risks, from fire safety to lone working, keeping you compliant and your team safe. Download the free Risk Assessment Toolkit
Should investors sell immediately? Or is it worth buying Diginex?
So far, investors are not buying the narrative. On the day of the announcement, Diginex closed at $1.06, down 3.64%. The next session it fell a further 5.45% to $1.04, before recovering modestly to $1.06 in after-hours trading. The weekly loss stands at roughly 26%, and the monthly decline has exceeded 40%.
Technical indicators paint a bleak picture. The stock’s annualized volatility is running at nearly 156%. The Relative Strength Index (RSI) has fallen to 30.7, a level that typically signals oversold conditions — but market observers caution that the slide reflects a fundamental lack of commercial substance behind the product news. No customer names or contract values accompanied the launch, and management offered no firm timeline for upcoming features.
Compounding the uncertainty is the planned acquisition of Resulticks, a customer-engagement specialist. Diginex has said the deal could bring in around $150 million in annual revenue and EBITDA of $46 million to $50 million — all contingent on closing. The original long-stop date of May 29 has been pushed to June 12, 2026, as the company works through outstanding conditions.
The combination of a new product launch that has failed to impress the Street and a transformative acquisition that remains unconsummated leaves Diginex in a precarious position. Whether the stock finds a floor after the Resulticks deal closes — or whether the continued selling reflects deeper doubts about the platform’s revenue potential — will become clearer in the coming weeks.
Ad
Diginex Stock: Buy or Sell?! New Diginex Analysis from June 5 delivers the answer:
The latest Diginex figures speak for themselves: Urgent action needed for Diginex investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from June 5.
Diginex: Buy or sell? Read more here...
